Following March inspection, Novo Nordisk’s semaglutide manufacturing facility cited by FDA

The FDA on Tues­day re­leased an in­spec­tion re­port sent to No­vo Nordisk ear­li­er this year cit­ing qual­i­ty-re­lat­ed is­sues at a site in Kalund­borg, Den­mark, that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.